Fig. 5: Schematic representation of the ROME trial design.
From: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
The patient flow is shown from the left to right of the figure. The upper boxes represent the two main eligibility criteria, molecular profiling, MTB evaluation, randomization, treatment with TT or SoC and possible crossover at disease progression. The central blue boxes indicate the study phases. The lower boxes summarize the main study characteristics (left) and the study endpoints (right). CGP, comprehensive genomic profiling; PD, progressive disease; R, randomization.
